| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 603259.CN | WuXi AppTec Co., Ltd. Class A | 83.9 | ¤69,933 | CN |
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 76.0 | ¤12,019 | CN |
| 002653.CN | Haisco Pharmaceutical Group Co. Ltd. Cla | 67.8 | ¤10,919 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 89.4 | ¤7,633 | CN |
| 688336.CN | Sunshine Guojian Pharmaceutical (Shangha | 91.1 | ¤5,796 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300515.CN | Hunan Sundy Science and Technology Co., | 79.4 | ¤477 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 55.4 | ¤543 | CN |
| 603998.CN | Hunan Fangsheng Pharmaceutical Co., Ltd. | 66.6 | ¤660 | CN |
| 688580.CN | Nanjing Vishee Medical Technology Co., L | 61.9 | ¤666 | CN |
| 300871.CN | Hvsen Biotechnology Co. Ltd. Class A | 60.0 | ¤685 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 76.0 | 21 | CN |
| 000423.CN | Dong-E-E-Jiao Co., Ltd. Class A | 64.5 | 20 | CN |
| 600285.CN | Henan Lingrui Pharmaceutial Co., Ltd. Cl | 60.3 | 10 | CN |
| 600867.CN | Tonghua Dongbao Pharmaceutical Co., Ltd. | 60.4 | 10 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 55.4 | 8 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 68.4 | 8 | CN |
| 002603.CN | Shijiazhuang Yiling Pharmaceutical Co., | 62.2 | 6 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 89.4 | 6 | CN |
| 002437.CN | Harbin Gloria Pharmaceuticals Co., Ltd. | 60.6 | 5 | CN |
| 300206.CN | Edan Instruments, Inc. Class A | 66.3 | 5 | CN |
| Average Market Cap | ¤4,986 |
| Median Market Cap | ¤1,419 |
| Avg. 3 Mo. Dollar Vol. | ¤92,156,513 |
| Avg. 3 Mo. Trading Vol. | 19,885,836 |
| Last Rebalance Date | 06/15/2026 |
| Companies Replaced | 16 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 22.9 |
| Forward P/E Ratio (12 Mo.) | 20.4 |
| Price/Book Ratio | 3.4 |
| Avg. Revenue Chg. - 3 Yr | 55.2% |
| Avg. Op. Income Chg. - 3 Yr. | 53.6% |
| Avg. EPS Growth - 3 Yr. | 19.2% |
| Avg. EPS Growth - 1 Yr. | 12.9% |
| Avg. Operating Margin | 20.4% |
| Avg. LT Debt to Total Capital | 6.5% |
| Avg. Return on Equity | 15.8% |
| Dividend Yield | 1.3% |
| China Health Care Index | 64.4 |
| China | 100.0% |
